Company Profile
Longboard Pharmaceuticals Stock Price, News & Analysis
Company overview
Business overview
Longboard Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Longboard Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Longboard Pharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Longboard Pharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
LBPH is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Longboard’s catalyst is bexicaserin in pediatric and rare epilepsies, with dose and efficacy updates doing most of the work. The company is still very much a one-program story.
Recent news
The five most recent feed items are shown below in reverse chronological order.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.